Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment Barriers & Adherence to AIs Among BC Survivors

Cancer; ePub 2016 Aug 29; Brier, Chambless, et al

In breast cancer survivors, greater perceived barriers appear to predict nonadherence to hormonal therapies such as aromatase inhibitors (AIs), a recent study found. Postmenopausal women with early-stage, estrogen receptor-positive breast cancer who were currently receiving treatment with an AI completed the 3-factor Health Beliefs and Medication Adherence in Breast Cancer scale and questionnaire. Researchers found:

• Among 437 participants, 93 (21.3%) were nonadherent.

• Women who perceived greater barriers to their AI treatment were more likely to demonstrate AI nonadherence behaviors by the end of their treatment period compared to those who reported fewer barriers (OR, 1.71).

• Conversely, perceived susceptibility to cancer recurrence and perceived benefits of AIs did not appear to predict AI adherence.

• Minority participants had a lower perceived susceptibility to breast cancer recurrence and higher perceived barriers to AI treatment.

Citation:

Brier MJ, Chambless DL, Gross R, Chen J, Mao JJ. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. [Published online ahead of print August 29, 2016]. Cancer. doi:10.1002/cncr.30318.